files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
About US
Editors
Issues
Pages
Indexed in
108
Views
4
Downloads

To Evaluate the Efficacy and Safety of Canagliflozin in Patients of Type 2 Diabetes Mellitus Inadequately Controlled on Maximum Dose of Three Oral Hypoglycemic Agents

Quazi Zubair Zafar, Maaz Hussain Syed, Shaikh Huzaif, Imran Nawaz Khan and Shaikh Ubedullah
Page: 292-296 | Received 25 Sep 2024, Accepted 26 Dec 2024, Published online: 26 Dec 2024

Download Citation
https://doi.org/10.36478/10.36478/makrjms.2025.1.292.296

Full Text Reference XML File PDF File

Abstract

Control over hyperglycemia is essential in type 2 DM management to reduce the complications. Many patients with type 2 diabetes are overweight or obese at the time of diagnosis. Weight reduction leads to improvement in glycemic control, lowers the HbA1c and risk of complications in patients with T2DM. SGLT‐2 inhibitor Canagliflozin demonstrated reduction in blood sugar, HbA1c and body weight in clinical studies. It was a prospective, open label, single arm, single centre, interventional study in which each patient treated for 24 weeks. Patients with age between 18‐65 years, have type 2 diabetes mellitus with HbA1c >8.5% and BMI > 25kg/m2 and on maximum dose of three OHA but inadequate response and willing to give written informed consent were included in the study. After 24 weeks of treatment, compared to baseline, mean HbA1c was decreased by ‐1.565% at 3 months and ‐3.02% at the end of 6 months interval. Mean FBS was reduced by 25.15mg/dL and 46.76mg/dL and mean PPBS was decreased by ‐54.34mg/dL and ‐87.41mg/dL after 3 and 6 months respectively. Mean change in HbA1c and fasting and postprandial blood sugar are statistically significant (P< 0.0001). We found significant reduction in mean weight (‐4.313 Kg) at the end of 6 months treatment. Canagliflozin is effective and safe drug to decrease HBA1c, blood sugar and weight in type 2 Diabetes mellitus patients failed to respond triple drug therapy of oral hypoglycemic drugs.

How to cite this article:

Quazi Zubair Zafar, Maaz Hussain Syed, Shaikh Huzaif, Imran Nawaz Khan and Shaikh Ubedullah. To Evaluate the Efficacy and Safety of Canagliflozin in Patients of Type 2 Diabetes Mellitus Inadequately Controlled on Maximum Dose of Three Oral Hypoglycemic Agents.
DOI: https://doi.org/10.36478/10.36478/makrjms.2025.1.292.296
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2025.1.292.296